NASDAQ: SIBN
Si Bone Inc Stock

$16.39-0.01 (-0.06%)
Updated Feb 14, 2025
SIBN Price
$16.39
Fair Value Price
N/A
Market Cap
$687.37M
52 Week Low
$11.70
52 Week High
$20.96
P/E
-17.82x
P/B
4.17x
P/S
3.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$157.04M
Earnings
-$37.40M
Gross Margin
77.7%
Operating Margin
-21.57%
Profit Margin
-23.8%
Debt to Equity
0.38
Operating Cash Flow
-$16M
Beta
1.12
Next Earnings
Feb 24, 2025
Ex-Dividend
N/A
Next Dividend
N/A

SIBN Overview

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SIBN's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
D
SIBN
Ranked
#24 of 129

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$31.89A
$10.41A
$47.68A
View Top Medical Device Stocks

Be the first to know about important SIBN news, forecast changes, insider trades & much more!

SIBN News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SIBN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SIBN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SIBN is good value based on its book value relative to its share price (4.17x), compared to the US Medical Devices industry average (4.36x)
P/B vs Industry Valuation
SIBN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SIBN due diligence checks available for Premium users.

Valuation

SIBN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-17.82x
Industry
42.37x
Market
37.91x

SIBN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.17x
Industry
4.36x
SIBN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SIBN's financial health

Profit margin

Revenue
$40.3M
Net Income
-$6.6M
Profit Margin
-16.3%
SIBN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SIBN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$227.0M
Liabilities
$62.0M
Debt to equity
0.38
SIBN's short-term assets ($203.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SIBN's short-term assets ($203.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SIBN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SIBN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$302.0k
Investing
$3.8M
Financing
$155.0k
SIBN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SIBN vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SIBNB$687.37M-0.06%-17.82x4.17x
IRMDB$699.95M-0.32%37.32x8.39x
CTKBB$673.68M+0.19%0.01x1.75x
OFIXC$711.17M+1.58%-5.95x1.35x
SENSF$734.86M-5.34%-9.54x-42.77x

Si Bone Stock FAQ

What is Si Bone's quote symbol?

(NASDAQ: SIBN) Si Bone trades on the NASDAQ under the ticker symbol SIBN. Si Bone stock quotes can also be displayed as NASDAQ: SIBN.

If you're new to stock investing, here's how to buy Si Bone stock.

What is the 52 week high and low for Si Bone (NASDAQ: SIBN)?

(NASDAQ: SIBN) Si Bone's 52-week high was $20.96, and its 52-week low was $11.70. It is currently -21.8% from its 52-week high and 40.09% from its 52-week low.

How much is Si Bone stock worth today?

(NASDAQ: SIBN) Si Bone currently has 41,938,179 outstanding shares. With Si Bone stock trading at $16.39 per share, the total value of Si Bone stock (market capitalization) is $687.37M.

Si Bone stock was originally listed at a price of $20.06 in Oct 17, 2018. If you had invested in Si Bone stock at $20.06, your return over the last 6 years would have been -18.3%, for an annualized return of -3.31% (not including any dividends or dividend reinvestments).

How much is Si Bone's stock price per share?

(NASDAQ: SIBN) Si Bone stock price per share is $16.39 today (as of Feb 14, 2025).

What is Si Bone's Market Cap?

(NASDAQ: SIBN) Si Bone's market cap is $687.37M, as of Feb 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Si Bone's market cap is calculated by multiplying SIBN's current stock price of $16.39 by SIBN's total outstanding shares of 41,938,179.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.